Ligand Pharmaceuticals, Inc. (LGND) Reports Q4 Earnings of $0.24, Offers FY12 Sales Guidance
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $284.70 +3.45%
Revenue Growth %: -32.2%
Financial Fact:
Total operating costs and expenses: 16.15M
Today's EPS Names:
ALZN, ASPU, USAU, More
Revenue Growth %: -32.2%
Financial Fact:
Total operating costs and expenses: 16.15M
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q4 EPS of $0.24, versus $0.12 reported last year. Revenue for the quarter came in at $12.9 million, versus $3.9 million reported last year.
For 2012, Ligand currently estimates total revenues to be approximately $30 million.
For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.
For 2012, Ligand currently estimates total revenues to be approximately $30 million.
For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s said to plan value strategy overhaul to revive US sales growth
- Could Affirm be a $200 stock?
- Analysts eye Intuit investor day for signs estimates have troughed
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
